Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status: Window of treatment

E. Farkas, Martijn C. De Wilde, Amanda J. Kiliaan, Paul G M Luiten

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Neurodegenerative disorders, and dementia in particular, have been shown to have a cerebrovascular pathogenic component often in the form of reduced cerebral blood flow. The debate whether such a reduced brain perfusion is a primary trigger or a secondary symptom in the neuropathological progression of dementia has not been conclusively decided yet. However, compelling experimental evidence has been collected to demonstrate an initiating role of reduced cerebral blood flow in neurodegenerative processes. Along these lines, experimental cerebral hypoperfusion in rodents was shown to impair spatial learning and to generate neuronal damage and associated gliosis in sensitive brain regions like the hippocampus and frontoparietal cortex. Since suboptimal cerebral blood supply was thus identified as a potential trigger of cognitive decline, the improvement of cerebral blood flow in cognitive disorders has emerged as an alternative treatment to moderate the symptoms and to delay the onset of advanced dementia. Various drugs, such as cholinergic compounds, hemorheologic agents and vascular smooth muscle relaxants, have already been tested in some instances for their efficacy to increase brain perfusion. In this respect, both clinical and preclinical trials delivered positive data. Furthermore, not only the treatment but also the prevention of the development of cognitive deficiency can target the cerebrovascular system. For this purpose, long-chain polyunsaturated fatty acids derived from fish oil (also known as n-3 PUFAs) have been considered as dietary supplements. These fatty acids appeared particularly effective in the prevention of hypertension-associated vascular pathology. The present review provides an overview of the actions of these compounds focusing on cerebral blood flow, neurodegeneration and cognitive decline.

Original languageEnglish
Pages (from-to)365-376
Number of pages12
JournalDrugs of Today
Volume38
Issue number5
DOIs
Publication statusPublished - 2002

Fingerprint

Cerebrovascular Circulation
Dementia
Brain
Perfusion
Gliosis
Fish Oils
Omega-3 Fatty Acids
Dietary Supplements
Unsaturated Fatty Acids
Vascular Smooth Muscle
Neurodegenerative Diseases
Cholinergic Agents
Blood Vessels
Rodentia
Hippocampus
Fatty Acids
Clinical Trials
Pathology
Hypertension
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status : Window of treatment. / Farkas, E.; De Wilde, Martijn C.; Kiliaan, Amanda J.; Luiten, Paul G M.

In: Drugs of Today, Vol. 38, No. 5, 2002, p. 365-376.

Research output: Contribution to journalArticle

Farkas, E. ; De Wilde, Martijn C. ; Kiliaan, Amanda J. ; Luiten, Paul G M. / Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status : Window of treatment. In: Drugs of Today. 2002 ; Vol. 38, No. 5. pp. 365-376.
@article{ead0d507e8f94a04980bce3a9c0994b6,
title = "Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status: Window of treatment",
abstract = "Neurodegenerative disorders, and dementia in particular, have been shown to have a cerebrovascular pathogenic component often in the form of reduced cerebral blood flow. The debate whether such a reduced brain perfusion is a primary trigger or a secondary symptom in the neuropathological progression of dementia has not been conclusively decided yet. However, compelling experimental evidence has been collected to demonstrate an initiating role of reduced cerebral blood flow in neurodegenerative processes. Along these lines, experimental cerebral hypoperfusion in rodents was shown to impair spatial learning and to generate neuronal damage and associated gliosis in sensitive brain regions like the hippocampus and frontoparietal cortex. Since suboptimal cerebral blood supply was thus identified as a potential trigger of cognitive decline, the improvement of cerebral blood flow in cognitive disorders has emerged as an alternative treatment to moderate the symptoms and to delay the onset of advanced dementia. Various drugs, such as cholinergic compounds, hemorheologic agents and vascular smooth muscle relaxants, have already been tested in some instances for their efficacy to increase brain perfusion. In this respect, both clinical and preclinical trials delivered positive data. Furthermore, not only the treatment but also the prevention of the development of cognitive deficiency can target the cerebrovascular system. For this purpose, long-chain polyunsaturated fatty acids derived from fish oil (also known as n-3 PUFAs) have been considered as dietary supplements. These fatty acids appeared particularly effective in the prevention of hypertension-associated vascular pathology. The present review provides an overview of the actions of these compounds focusing on cerebral blood flow, neurodegeneration and cognitive decline.",
author = "E. Farkas and {De Wilde}, {Martijn C.} and Kiliaan, {Amanda J.} and Luiten, {Paul G M}",
year = "2002",
doi = "10.1358/dot.2002.38.5.677137",
language = "English",
volume = "38",
pages = "365--376",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Chronic cerebral hypoperfusion-related neuropathologic changes and compromised cognitive status

T2 - Window of treatment

AU - Farkas, E.

AU - De Wilde, Martijn C.

AU - Kiliaan, Amanda J.

AU - Luiten, Paul G M

PY - 2002

Y1 - 2002

N2 - Neurodegenerative disorders, and dementia in particular, have been shown to have a cerebrovascular pathogenic component often in the form of reduced cerebral blood flow. The debate whether such a reduced brain perfusion is a primary trigger or a secondary symptom in the neuropathological progression of dementia has not been conclusively decided yet. However, compelling experimental evidence has been collected to demonstrate an initiating role of reduced cerebral blood flow in neurodegenerative processes. Along these lines, experimental cerebral hypoperfusion in rodents was shown to impair spatial learning and to generate neuronal damage and associated gliosis in sensitive brain regions like the hippocampus and frontoparietal cortex. Since suboptimal cerebral blood supply was thus identified as a potential trigger of cognitive decline, the improvement of cerebral blood flow in cognitive disorders has emerged as an alternative treatment to moderate the symptoms and to delay the onset of advanced dementia. Various drugs, such as cholinergic compounds, hemorheologic agents and vascular smooth muscle relaxants, have already been tested in some instances for their efficacy to increase brain perfusion. In this respect, both clinical and preclinical trials delivered positive data. Furthermore, not only the treatment but also the prevention of the development of cognitive deficiency can target the cerebrovascular system. For this purpose, long-chain polyunsaturated fatty acids derived from fish oil (also known as n-3 PUFAs) have been considered as dietary supplements. These fatty acids appeared particularly effective in the prevention of hypertension-associated vascular pathology. The present review provides an overview of the actions of these compounds focusing on cerebral blood flow, neurodegeneration and cognitive decline.

AB - Neurodegenerative disorders, and dementia in particular, have been shown to have a cerebrovascular pathogenic component often in the form of reduced cerebral blood flow. The debate whether such a reduced brain perfusion is a primary trigger or a secondary symptom in the neuropathological progression of dementia has not been conclusively decided yet. However, compelling experimental evidence has been collected to demonstrate an initiating role of reduced cerebral blood flow in neurodegenerative processes. Along these lines, experimental cerebral hypoperfusion in rodents was shown to impair spatial learning and to generate neuronal damage and associated gliosis in sensitive brain regions like the hippocampus and frontoparietal cortex. Since suboptimal cerebral blood supply was thus identified as a potential trigger of cognitive decline, the improvement of cerebral blood flow in cognitive disorders has emerged as an alternative treatment to moderate the symptoms and to delay the onset of advanced dementia. Various drugs, such as cholinergic compounds, hemorheologic agents and vascular smooth muscle relaxants, have already been tested in some instances for their efficacy to increase brain perfusion. In this respect, both clinical and preclinical trials delivered positive data. Furthermore, not only the treatment but also the prevention of the development of cognitive deficiency can target the cerebrovascular system. For this purpose, long-chain polyunsaturated fatty acids derived from fish oil (also known as n-3 PUFAs) have been considered as dietary supplements. These fatty acids appeared particularly effective in the prevention of hypertension-associated vascular pathology. The present review provides an overview of the actions of these compounds focusing on cerebral blood flow, neurodegeneration and cognitive decline.

UR - http://www.scopus.com/inward/record.url?scp=0036266871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036266871&partnerID=8YFLogxK

U2 - 10.1358/dot.2002.38.5.677137

DO - 10.1358/dot.2002.38.5.677137

M3 - Article

C2 - 12532171

AN - SCOPUS:0036266871

VL - 38

SP - 365

EP - 376

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 5

ER -